Citation & Authors
Arthritis Rheumatol. 2026;78(3):592–602.
ABSTRACT · RESEARCH SUMMARY
Research summary
The TriNetX target trial emulation compared treatments for RA-ILD, with 1,615 patients per group after matching. Abatacept was associated with lower risks of death (HR 0.689; 95% CI 0.581–0.818) and mechanical ventilation (0.698; 0.521–0.934), with consistent directions in sensitivity analyses. However, clinicians may preferentially prescribe abatacept to patients with milder disease. Confounding by indication cannot be excluded, and a causal survival advantage cannot be established.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
Key findings
After matching, each group included 1,615 patients. Abatacept was associated with a lower risk of all-cause mortality (HR 0.689; 95% CI 0.581–0.818).
Residual confounding related to treatment indication and disease severity may remain; causality cannot be established from these findings.
